Lutz Frankenstein

List of Publications by Year
in descending order

74 papers	1,925 citations	279798 23 h-index	289244 40 g-index
74 all docs	74 docs citations	74 times ranked	3533 citing authors

#	Article	IF	Citations
1	Assessment of myocardial deformation with cardiac magnetic resonance strain imaging improves risk stratification in patients with dilated cardiomyopathy. European Heart Journal Cardiovascular Imaging, 2015, 16, 307-315.	1.2	211
2	Effect of Availability of Transcatheter Aortic-Valve Replacement on Clinical Practice. New England Journal of Medicine, 2015, 373, 2438-2447.	27.0	198
3	Biological Variation and Reference Change Value of High-Sensitivity Troponin T in Healthy Individuals during Short and Intermediate Follow-up Periods. Clinical Chemistry, 2011, 57, 1068-1071.	3.2	115
4	Respiratory muscle function and exercise intolerance in heart failure. Current Heart Failure Reports, 2009, 6, 95-101.	3.3	103
5	Biomarker Changes after Strenuous Exercise Can Mimic Pulmonary Embolism and Cardiac Injury—A Metaanalysis of 45 Studies. Clinical Chemistry, 2015, 61, 1246-1255.	3.2	81
6	Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. Journal of Heart and Lung Transplantation, 2018, 37, 611-618.	0.6	66
7	Anxiety and self-care behaviour in patients with chronic systolic heart failure: A multivariate model. European Journal of Cardiovascular Nursing, 2018, 17, 170-177.	0.9	52
8	Minimal important difference for 6-minute walk test distances among patients with chronic heart failure. International Journal of Cardiology, 2014, 176, 94-98.	1.7	51
9	Left ventricular long axis strain: a new prognosticator in non-ischemic dilated cardiomyopathy?. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 36.	3.3	51
10	Economic evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarction using the high-sensitivity cardiac troponin T assay in the emergency department. PLoS ONE, 2017, 12, e0187662.	2.5	48
11	Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status. European Heart Journal, 2008, 29, 2634-2640.	2.2	35
12	The obesity paradox in stable chronic heart failure does not persist after matching for indicators of disease severity and confounders. European Journal of Heart Failure, 2009, 11, 1189-1194.	7.1	35
13	Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. Chest, 2019, 156, 706-714.	0.8	33
14	The association between long‐term longitudinal trends in guideline adherence and mortality in relation to age and sex. European Journal of Heart Failure, 2010, 12, 574-580.	7.1	30
15	Validity, prognostic value and optimal cutoff of respiratory muscle strength in patients with chronic heart failure changes with beta-blocker treatment. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 424-429.	2.8	29
16	A decade of developments in chronic heart failure treatment: a comparison of therapy and outcome in a secondary and tertiary hospital setting. Clinical Research in Cardiology, 2012, 101, 1-10.	3.3	29
17	The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. Clinical Research in Cardiology, 2018, 107, 460-470.	3.3	29
18	Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2016, 9, 2137-2143.	2.9	28

#	Article	IF	Citations
19	Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy. Drug Design, Development and Therapy, 2014, 9, 93.	4.3	27
20	Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clinical Research in Cardiology, 2017, 106, 711-721.	3.3	27
21	Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Failure Reviews, 2021, 26, 1421-1435.	3.9	26
22	Variability of N-Terminal Probrain Natriuretic Peptide in Stable Chronic Heart Failure and Its Relation to Changes in Clinical Variables. Clinical Chemistry, 2009, 55, 923-929.	3.2	25
23	Biological variation of high sensitive Troponin T in stable heart failure patients with ischemic or dilated cardiomyopathy. Clinical Research in Cardiology, 2011, 100, 633-640.	3.3	24
24	Volume–outcome relationship in transcatheter aortic valve implantations in Germany 2008–2014: a secondary data analysis of electronic health records. BMJ Open, 2018, 8, e020204.	1.9	22
25	Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. Clinical Research in Cardiology, 2022, 111, 428-439.	3.3	22
26	Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation. Drug Design, Development and Therapy, 2016, 10, 677.	4.3	21
27	The need for dedicated advanced heart failure units to optimize heart failure care: impact of optimized advanced heart failure unit care on heart transplant outcome in high‑risk patients. ESC Heart Failure, 2018, 5, 1108-1117.	3.1	21
28	Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure. Circulation: Heart Failure, 2015, 8, 887-896.	3.9	20
29	Learning Curves Among All Patients Undergoing Transcatheter Aortic Valve Implantation in Germany: A Retrospective Observational Study. International Journal of Cardiology, 2017, 235, 17-21.	1.7	20
30	Haemodynamic effects of percutaneous mitral valve edge‑to‑edge repair in patients with end‑stage heart failure awaiting heart transplantation. ESC Heart Failure, 2018, 5, 892-901.	3.1	20
31	Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease. American Heart Journal, 2016, 178, 28-36.	2.7	19
32	Reference change values and determinants of variability of NT-proANP and GDF15 in stable chronic heart failure. Basic Research in Cardiology, 2009, 104, 731-738.	5.9	18
33	Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe. Heart, 2019, 105, 1252-1259.	2.9	18
34	Is serial determination of inspiratory muscle strength a useful prognostic marker in chronic heart failure?. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 156-161.	2.8	17
35	Influence of Sex on Treatment and Outcome in Chronic Heart Failure. Cardiovascular Therapeutics, 2012, 30, 182-192.	2.5	17
36	Peritoneal ultrafiltration in end-stage chronic heart failure. CKJ: Clinical Kidney Journal, 2015, 8, 219-225.	2.9	17

#	Article	IF	Citations
37	Cost analysis of early discharge using combined copeptin/cardiac troponin testing versus serial cardiac troponin testing in patients with suspected acute coronary syndrome. PLoS ONE, 2018, 13, e0202133.	2.5	15
38	A patient-centered perspective of treating depressive symptoms in chronic heart failure: What do patients prefer?. Patient Education and Counseling, 2015, 98, 783-787.	2.2	14
39	READY: relative efficacy of loop diuretics in patients with chronic systolic heart failureâ€"a systematic review and network meta-analysis of randomised trials. Heart Failure Reviews, 2019, 24, 461-472.	3.9	14
40	Advantageous effects of immunosuppression with&nbsp;tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart&nbsp;transplantation. Drug Design, Development and Therapy, 2015, 9, 1217.	4.3	13
41	Multidisciplinary Approach for Patients Hospitalized With Heart Failure. Revista Espanola De Cardiologia (English Ed), 2015, 68, 885-891.	0.6	13
42	Biological variation, reference change value (RCV) and minimal important difference (MID) of inspiratory muscle strength (PImax) in patients with stable chronic heart failure. Clinical Research in Cardiology, 2015, 104, 822-830.	3.3	12
43	Long-term outcome of patients with and without super-response to CRT-D. Clinical Research in Cardiology, 2016, 105, 341-348.	3.3	12
44	Percutaneous repair of mitral valve regurgitation in patients with severe heart failure: comparison with optimal medical treatment. Acta Cardiologica, 2018, 73, 378-386.	0.9	12
45	An analysis of the cost-effectiveness of transcatheter mitral valve repair for people with secondary mitral valve regurgitation in the UK. Journal of Medical Economics, 2020, 23, 1425-1434.	2.1	12
46	Prevalence and prognostic significance of adrenergic escape during chronic Î²â€‘blocker therapy in chronic heart failure. European Journal of Heart Failure, 2009, 11, 178-184.	7.1	11
47	Abordaje multidisciplinario en pacientes hospitalizados por insuficiencia cardiaca. Revista Espanola De Cardiologia, 2015, 68, 885-891.	1.2	11
48	Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 82-92.	3.0	11
49	Temporary oral anticoagulation after MitraClip â€" a strategy to lower the incidence of post-procedural stroke?. Acta Cardiologica, 2020, 75, 61-67.	0.9	11
50	Beta-Blockers Influence the Short-term and Long-term Prognostic Information of Natriuretic Peptides and Catecholamines in Chronic Heart Failure Independent From Specific Agents. Journal of Heart and Lung Transplantation, 2007, 26, 1033-1039.	0.6	10
51	Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy. Clinical Research in Cardiology, 2018, 107, 1040-1049.	3.3	10
52	Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure â€" A multicenter propensity score matched analysis. International Journal of Cardiology, 2019, 289, 83-90.	1.7	10
53	The chameleon of cardiology: cardiac sarcoidosis before and after heart transplantation. ESC Heart Failure, 2020, 7, 692-696.	3.1	10
54	Primary ICD-therapy in patients with advanced heart failure: selection strategies and future trials. Clinical Research in Cardiology, 2008, 97, 594-600.	3.3	9

#	Article	IF	Citations
55	Clinical characteristics, morbidity, and prognostic value of concomitant coronary artery disease in idiopathic dilated cardiomyopathy. Clinical Research in Cardiology, 2013, 102, 771-780.	3.3	9
56	Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failure. Clinical Research in Cardiology, 2017, 106, 974-985.	3.3	9
57	The impact of post-procedural complications on reimbursement, length of stay and mechanical ventilation among patients undergoing transcatheter aortic valve implantation in Germany. European Journal of Health Economics, 2018, 19, 223-228.	2.8	9
58	Predicting hospitalization and mortality in patients with heart failure: The BARDICHE-index. International Journal of Cardiology, 2017, 227, 901-907.	1.7	8
59	Unidimensional Longitudinal Strain: A Simple Approach for the Assessment of Longitudinal Myocardial Deformation by Echocardiography. Journal of the American Society of Echocardiography, 2018, 31, 733-742.	2.8	8
60	Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials. Heart Failure Reviews, 2020, 25, 161-171.	3.9	8
61	Cross‑lagged analyses of the bidirectional relationship between depression and markers of chronic heart failure. Depression and Anxiety, 2020, 37, 898-907.	4.1	8
62	Biological variation of the cardiac index in patients with stable chronic heart failure: inert gas rebreathing compared with impedance cardiography. ESC Heart Failure, 2015, 2, 112-120.	3.1	7
63	Long-term biological variation of high-sensitivity cardiac troponin T using minimal important differences and reference change values in stable outpatients with cardiovascular disease. Clinical Biochemistry, 2019, 67, 7-11.	1.9	7
64	Sex-specific Predictive Power of 6-Minute Walk Test in Chronic Heart Failure Is Not Enhanced Using Percent Achieved of Published Reference Equations. Journal of Heart and Lung Transplantation, 2008, 27, 427-434.	0.6	6
65	Conversion to generic cyclosporine A in stable chronic patients after heart transplantation. Drug Design, Development and Therapy, 2013, 7, 1421.	4.3	6
66	Etiology-specific assessment of predictors of long-term survival in chronic systolic heart failure. IJC Heart and Vasculature, 2015, 7, 61-68.	1.1	5
67	Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. International Journal of Cardiology, 2017, 238, 97-104.	1.7	5
68	Prognostic value of changes in high-sensitivity cardiac troponin T beyond biological variation in stable outpatients with cardiovascular disease: a validation study. Clinical Research in Cardiology, 2022, 111, 333-342.	3.3	4
69	Hemodynamic Determinants of the Biologic Variation of N-Terminal Pro‑B-Type Natriuretic Peptide in Patients With Stable Systolic Chronic Heart Failure. Journal of Cardiac Failure, 2017, 23, 835-842.	1.7	3
70	Potential role for clinical calibration to increase engagement with and application of home telemonitoring: a report from the HeartCycle programme. ESC Heart Failure, 2017, 4, 66-70.	3.1	2
71	N‑terminal pro brain natriuretic peptide eliminates the prognostic effect of atrial fibrillation in patients with chronic heart failure. ESC Heart Failure, 2019, 6, 640-648.	3.1	2
72	The role of diabetes in cardiomyopathies of different etiologies‑Characteristics and 1-year follow-up results of the EVITA-HF registry. PLoS ONE, 2020, 15, e0234260.	2.5	2

#	Article	IF	Citations
73	The Difficult Task of Finding the Best Antihypertensive Agent. Archives of Internal Medicine, 2011, 171, 394-5.	3.8	1
74	Impact of the introduction of percutaneous edge-to-edge mitral valve reconstruction on clinical practice in Germany compared to surgical valve repair. Clinical Research in Cardiology, 2021, 110, 620-627.	3.3	1